[{"id":"faecb63e-ceb1-42d4-81de-58e59c1de21c","acronym":"KETOACRO","url":"https://clinicaltrials.gov/study/NCT06949891","created_at":"2025-09-07T01:25:58.833Z","updated_at":"2025-09-07T01:25:58.833Z","phase":"","brief_title":"KETOgenic Diet Therapy in Patients With ACROmegaly","source_id_and_acronym":"NCT06949891 - KETOACRO","lead_sponsor":"Erasmus Medical Center","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-04-29"},{"id":"96a46201-6c05-499a-b5e8-480c4ba52158","acronym":"","url":"https://clinicaltrials.gov/study/NCT03382158","created_at":"2021-01-18T16:41:19.886Z","updated_at":"2025-02-25T17:29:36.962Z","phase":"","brief_title":"International PPB/DICER1 Registry","source_id_and_acronym":"NCT03382158","lead_sponsor":"Children's Hospitals and Clinics of Minnesota","biomarkers":" DICER1","pipe":"","alterations":" ","tags":["DICER1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 3400","initiation":"Initiation: 12/06/2016","start_date":" 12/06/2016","primary_txt":" Primary completion: 12/06/2030","primary_completion_date":" 12/06/2030","study_txt":" Completion: 12/06/2035","study_completion_date":" 12/06/2035","last_update_posted":"2025-01-30"},{"id":"b02d7446-9c2e-44de-aefb-87c2ab738292","acronym":"DOMINO START","url":"https://clinicaltrials.gov/study/NCT04081701","created_at":"2021-01-18T19:59:05.539Z","updated_at":"2025-02-25T15:43:40.367Z","phase":"Phase 4","brief_title":"68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.","source_id_and_acronym":"NCT04081701 - DOMINO START","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 12/31/2038","primary_completion_date":" 12/31/2038","study_txt":" Completion: 12/31/2038","study_completion_date":" 12/31/2038","last_update_posted":"2024-12-19"},{"id":"c07855c1-fe1a-4490-964f-cb44bb232d4a","acronym":"PitNET2024","url":"https://clinicaltrials.gov/study/NCT06607198","created_at":"2025-02-26T14:54:58.548Z","updated_at":"2025-02-26T14:54:58.548Z","phase":"","brief_title":"Clinical-pathological Evaluation of Pit-NETs","source_id_and_acronym":"NCT06607198 - PitNET2024","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 940","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-09-23"},{"id":"7b6a4335-88ee-4c63-a5cb-29fd6154bfa1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05822817","created_at":"2023-04-21T15:04:19.078Z","updated_at":"2024-07-02T16:35:06.715Z","phase":"Phase 4","brief_title":"Comparison of Postoperative Recovery of Sevoflurane and Propofol After Transsphenoidal Surgery","source_id_and_acronym":"NCT05822817","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" PRL","pipe":"","alterations":" ","tags":["PRL"],"overall_status":"Recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-05-01"},{"id":"9461158e-5d26-4049-990e-1b882bc14200","acronym":"","url":"https://clinicaltrials.gov/study/NCT06295952","created_at":"2024-03-06T21:33:56.543Z","updated_at":"2024-07-02T16:35:06.703Z","phase":"Phase 2","brief_title":"A Study of Pasireotide in People With Prolactinoma","source_id_and_acronym":"NCT06295952","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PRL","pipe":"","alterations":" ","tags":["PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor (pasireotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/27/2024","start_date":" 02/27/2024","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-05-01"},{"id":"2abc8b5e-bbff-4610-b944-f367032e5447","acronym":"","url":"https://clinicaltrials.gov/study/NCT06156020","created_at":"2023-12-09T16:35:00.738Z","updated_at":"2024-07-02T16:35:13.394Z","phase":"","brief_title":"Outcome Analysis of Endoscopic Resection of Pituitary Adenomas","source_id_and_acronym":"NCT06156020","lead_sponsor":"National Cheng-Kung University Hospital","biomarkers":" IGF1 • PRL","pipe":"","alterations":" ","tags":["IGF1 • PRL"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-21"},{"id":"83a011cc-3ed7-453f-8d6a-4bfef59bfc3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03583528","created_at":"2021-01-18T17:37:43.597Z","updated_at":"2024-07-02T16:35:22.583Z","phase":"","brief_title":"DOTATOC PET/CT for Imaging NET Patients","source_id_and_acronym":"NCT03583528","lead_sponsor":"British Columbia Cancer Agency","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 07/11/2018","start_date":" 07/11/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-01-23"},{"id":"389216a5-645b-4983-940f-d8c2ebd77daf","acronym":"PPB","url":"https://clinicaltrials.gov/study/NCT00565903","created_at":"2021-01-18T02:03:50.302Z","updated_at":"2024-07-02T16:35:54.363Z","phase":"","brief_title":"Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome","source_id_and_acronym":"NCT00565903 - PPB","lead_sponsor":"Ashley Hill","biomarkers":" DICER1","pipe":"","alterations":" ","tags":["DICER1"],"overall_status":"Completed","enrollment":" Enrollment 1247","initiation":"Initiation: 03/01/2005","start_date":" 03/01/2005","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2023-03-01"},{"id":"667cb8dc-8d8d-495c-9a37-353a4b66ee7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04284605","created_at":"2021-02-09T07:59:16.150Z","updated_at":"2024-07-02T16:36:22.350Z","phase":"","brief_title":"Effects Exercise Training in Patients With Pituitary Adenoma","source_id_and_acronym":"NCT04284605","lead_sponsor":"Hacettepe University","biomarkers":" IL6 • IL1B","pipe":"","alterations":" ","tags":["IL6 • IL1B"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 05/15/2020","start_date":" 05/15/2020","primary_txt":" Primary completion: 09/15/2021","primary_completion_date":" 09/15/2021","study_txt":" Completion: 10/15/2021","study_completion_date":" 10/15/2021","last_update_posted":"2021-10-27"},{"id":"2f82011e-c022-4733-a6ee-5085e9efec4d","acronym":"EpidemioPIT","url":"https://clinicaltrials.gov/study/NCT03973450","created_at":"2021-07-27T21:53:46.263Z","updated_at":"2024-07-02T16:36:24.760Z","phase":"","brief_title":"Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia","source_id_and_acronym":"NCT03973450 - EpidemioPIT","lead_sponsor":"Neuromed IRCCS","biomarkers":" MEN1","pipe":"","alterations":" ","tags":["MEN1"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 06/15/2019","start_date":" 06/15/2019","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 02/28/2022","study_completion_date":" 02/28/2022","last_update_posted":"2021-09-08"},{"id":"34eceedd-bc69-4ed1-bbff-0cc66fe8b494","acronym":"","url":"https://clinicaltrials.gov/study/NCT05005715","created_at":"2021-08-13T12:53:42.468Z","updated_at":"2024-07-02T16:36:26.358Z","phase":"Phase 2","brief_title":"Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery","source_id_and_acronym":"NCT05005715","lead_sponsor":"Seoul National University Hospital","biomarkers":" IGF1 • PRL","pipe":"","alterations":" ","tags":["IGF1 • PRL"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 08/30/2021","start_date":" 08/30/2021","primary_txt":" Primary completion: 08/29/2022","primary_completion_date":" 08/29/2022","study_txt":" Completion: 08/29/2023","study_completion_date":" 08/29/2023","last_update_posted":"2021-08-13"},{"id":"255ffbc3-1ae8-4087-ae88-e4e032dedb1a","acronym":"IMPEC","url":"https://clinicaltrials.gov/study/NCT03346954","created_at":"2021-01-18T16:31:45.427Z","updated_at":"2024-07-02T16:36:37.966Z","phase":"","brief_title":"Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease","source_id_and_acronym":"NCT03346954 - IMPEC","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" TP53","pipe":" | ","alterations":" TP53 expression","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 12/11/2017","start_date":" 12/11/2017","primary_txt":" Primary completion: 06/11/2019","primary_completion_date":" 06/11/2019","study_txt":" Completion: 08/31/2020","study_completion_date":" 08/31/2020","last_update_posted":"2020-12-01"},{"id":"e42eb410-d233-4da3-81be-254dd0eb71ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT00001981","created_at":"2021-01-17T22:45:58.047Z","updated_at":"2024-07-02T16:36:38.101Z","phase":"","brief_title":"The Treatment and Natural History of Acromegaly","source_id_and_acronym":"NCT00001981","lead_sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 10/02/1991","start_date":" 10/02/1991","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 11/20/2020","study_completion_date":" 11/20/2020","last_update_posted":"2020-11-27"},{"id":"b547277c-5469-455b-a6eb-bbd53c10441a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04106843","created_at":"2021-01-18T20:05:02.856Z","updated_at":"2024-07-02T16:36:41.314Z","phase":"Phase 2","brief_title":"Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers","source_id_and_acronym":"NCT04106843","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SSTR • IGF1","pipe":"","alterations":" ","tags":["SSTR • IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/13/2019","start_date":" 06/13/2019","primary_txt":" Primary completion: 09/03/2020","primary_completion_date":" 09/03/2020","study_txt":" Completion: 09/03/2020","study_completion_date":" 09/03/2020","last_update_posted":"2020-09-07"},{"id":"f6621e14-c44d-47c1-ada5-9bd1bc877ebb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04529356","created_at":"2021-01-18T21:41:15.455Z","updated_at":"2024-07-02T16:36:41.647Z","phase":"","brief_title":"The TMS Treatment for Postoperative Headache in GH Tumor","source_id_and_acronym":"NCT04529356","lead_sponsor":"Huashan Hospital","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 09/30/2022","study_completion_date":" 09/30/2022","last_update_posted":"2020-08-27"},{"id":"1d2806c4-6266-4455-9731-65d694163d34","acronym":"","url":"https://clinicaltrials.gov/study/NCT00601289","created_at":"2021-01-18T02:13:42.025Z","updated_at":"2024-07-02T16:36:42.548Z","phase":"Phase 2","brief_title":"Temozolomide in Treating Patients With Invasive Pituitary Tumors","source_id_and_acronym":"NCT00601289","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" IGF1 • PRL","pipe":"","alterations":" ","tags":["IGF1 • PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":"","study_completion_date":"","last_update_posted":"2020-07-31"},{"id":"7f03c3f7-74dd-4581-a823-0407a28b50a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03457389","created_at":"2021-01-18T17:02:43.890Z","updated_at":"2024-07-02T16:36:48.260Z","phase":"","brief_title":"Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma","source_id_and_acronym":"NCT03457389","lead_sponsor":"Seoul National University Hospital","biomarkers":" PRL","pipe":"","alterations":" ","tags":["PRL"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/22/2018","start_date":" 02/22/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2020-03-18"},{"id":"811639d5-0c26-4ce1-88d6-9c82ddcf4614","acronym":"","url":"https://clinicaltrials.gov/study/NCT00939523","created_at":"2023-03-23T22:06:57.177Z","updated_at":"2024-07-02T16:36:51.052Z","phase":"Phase 2","brief_title":"Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy","source_id_and_acronym":"NCT00939523","lead_sponsor":"Cedars-Sinai Medical Center","biomarkers":" EGFR • HER-2","pipe":"","alterations":" ","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2020-01-22"},{"id":"ce540c17-ccf2-4643-bcd9-84218b6de1fa","acronym":"Passion I","url":"https://clinicaltrials.gov/study/NCT01283542","created_at":"2021-02-09T07:54:16.394Z","updated_at":"2024-07-02T16:37:00.170Z","phase":"Phase 2","brief_title":"Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.","source_id_and_acronym":"NCT01283542 - Passion I","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/26/2012","start_date":" 11/26/2012","primary_txt":" Primary completion: 09/12/2017","primary_completion_date":" 09/12/2017","study_txt":" Completion: 09/12/2017","study_completion_date":" 09/12/2017","last_update_posted":"2019-04-26"},{"id":"09359f46-0ac9-4649-abb8-2c92744c542f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03714763","created_at":"2021-02-09T07:58:47.369Z","updated_at":"2024-07-02T16:37:05.869Z","phase":"","brief_title":"Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)","source_id_and_acronym":"NCT03714763","lead_sponsor":"Zhebao Wu","biomarkers":" PRL","pipe":"","alterations":" ","tags":["PRL"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 01/31/2022","study_completion_date":" 01/31/2022","last_update_posted":"2018-10-22"},{"id":"361f5eb9-0bc0-4cb0-a8c0-a394466a8db6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02574793","created_at":"2021-02-09T07:56:38.696Z","updated_at":"2024-07-02T16:37:14.570Z","phase":"","brief_title":"Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects","source_id_and_acronym":"NCT02574793","lead_sponsor":"Huashan Hospital","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 12/31/2017","primary_completion_date":" 12/31/2017","study_txt":" Completion: 01/07/2018","study_completion_date":" 01/07/2018","last_update_posted":"2018-01-23"},{"id":"cc40bdbe-37b2-4036-8d3f-96cd3fbd7722","acronym":"","url":"https://clinicaltrials.gov/study/NCT03309319","created_at":"2021-01-18T16:20:37.062Z","updated_at":"2024-07-02T16:37:17.126Z","phase":"","brief_title":"A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas","source_id_and_acronym":"NCT03309319","lead_sponsor":"Zhaoyun Zhang","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rosiglitazone"],"overall_status":"Unknown status","enrollment":" Enrollment 24","initiation":"Initiation: 10/16/2016","start_date":" 10/16/2016","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 12/31/2018","study_completion_date":" 12/31/2018","last_update_posted":"2017-10-13"},{"id":"dbad78d8-facd-49a8-8a54-303be42ec140","acronym":"","url":"https://clinicaltrials.gov/study/NCT01371643","created_at":"2021-01-18T05:37:07.136Z","updated_at":"2024-07-02T16:37:29.515Z","phase":"Phase 4","brief_title":"Surgical Debulking of Pituitary Adenomas","source_id_and_acronym":"NCT01371643","lead_sponsor":"NYU Langone Health","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e octreotide acetate"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 04/01/2004","start_date":" 04/01/2004","primary_txt":" Primary completion: 07/01/2010","primary_completion_date":" 07/01/2010","study_txt":" Completion: 12/01/2011","study_completion_date":" 12/01/2011","last_update_posted":"2016-08-29"}]